GlassScriptPhysician profile
Paul A Marquette
NPI 1831128727
$5,691.30
in general payments reported to CMS, 2019-2025
43 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,793 · 2020: $201 · 2021: $192 · 2022: $99.83 · 2023: $1,105 · 2024: $1,180 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,405.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $885.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $700.24 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $616.63 | 2019-2025 | |
| Lilly USA, LLC | $590.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $472.24 | 2019-2025 | |
| Exact Sciences Corporation | $305.45 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $233.16 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.83 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $192.69 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $177.44 | 2020-2025 | Repatha, Otezla, Otezla |
| Genentech USA, INC. | $176.94 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $158.42 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $136.50 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $85.35 | 2019-2023 | Belsomra, Januvia |
| Bayer Healthcare Pharmaceuticals INC. | $78.12 | 2024-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Marquette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.